138 related articles for article (PubMed ID: 27936903)
1. Paradoxical increase in synthetic cannabinoid emergency-related presentations after a citywide ban: Lessons from Houston, Texas.
Mathai D; Gordon M; Muchmore P; Matorin A; Shah A; Moukaddam N
Bull Menninger Clin; 2016; 80(4):357-370. PubMed ID: 27936903
[TBL] [Abstract][Full Text] [Related]
2. Synthetic cannabinoid presentations decline following ban.
Christie G; MacFarlane V
Drug Alcohol Rev; 2016 Mar; 35(2):E3-4. PubMed ID: 26492870
[No Abstract] [Full Text] [Related]
3. "Spice" girls: synthetic cannabinoid intoxication.
Schneir AB; Cullen J; Ly BT
J Emerg Med; 2011 Mar; 40(3):296-9. PubMed ID: 21167669
[TBL] [Abstract][Full Text] [Related]
4. [Synthetic cannabinoids: A new addiction matrix].
Scocard A; Benyamina A; Coscas S; Karila L
Presse Med; 2017 Jan; 46(1):11-22. PubMed ID: 28063756
[TBL] [Abstract][Full Text] [Related]
5. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids.
Loeffler G; Delaney E; Hann M
Brain Res Bull; 2016 Sep; 126(Pt 1):8-28. PubMed ID: 27108542
[TBL] [Abstract][Full Text] [Related]
6. Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey.
Glue P; Courts J; Gray A; Patterson T
N Z Med J; 2016 Apr; 129(1433):37-40. PubMed ID: 27349159
[TBL] [Abstract][Full Text] [Related]
7. Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act.
Webb NE; Wood DM; Greene SL; Hunter LJ; Archer JRH; Dines AM; Dargan PI
Clin Toxicol (Phila); 2019 Jan; 57(1):36-41. PubMed ID: 30067112
[TBL] [Abstract][Full Text] [Related]
8. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016.
Springer YP; Gerona R; Scheunemann E; Shafer SL; Lin T; Banister SD; Cooper MP; Castrodale LJ; Levy M; Butler JC; McLaughlin JB
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(40):1108-1111. PubMed ID: 27736839
[TBL] [Abstract][Full Text] [Related]
9. A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure.
Gudsoorkar VS; Perez JA
Methodist Debakey Cardiovasc J; 2015; 11(3):189-91. PubMed ID: 26634029
[TBL] [Abstract][Full Text] [Related]
10. Organic and synthetic cannabinoid use in adolescents.
Bhatty S; Wu W
Pediatr Ann; 2013 Jan; 42(1):31-5. PubMed ID: 23316832
[No Abstract] [Full Text] [Related]
11. Reports of adverse health effects related to synthetic cannabinoid use in New York State.
Papadopoulos EA; Cummings KR; Marraffa JM; Aldous KM; Li L; Ahmad N
Am J Addict; 2017 Dec; 26(8):772-775. PubMed ID: 29105968
[TBL] [Abstract][Full Text] [Related]
12. How much can synthetic cannabinoid damage the heart? A case of cardiogenic shock following resistant ventricular fibrillation after synthetic cannabinoid use.
Yamanoglu A; Celebi Yamanoglu NG; Evran T; Sogut O
J Clin Ultrasound; 2018 Nov; 46(9):605-609. PubMed ID: 29479764
[TBL] [Abstract][Full Text] [Related]
13. Top 10 Facts You Need to Know About Synthetic Cannabinoids: Not So Nice Spice.
Kemp AM; Clark MS; Dobbs T; Galli R; Sherman J; Cox R
Am J Med; 2016 Mar; 129(3):240-4.e1. PubMed ID: 26522795
[TBL] [Abstract][Full Text] [Related]
14. The Role of Public Health in Combatting Synthetic Cannabinoid Use in Adolescents.
Warren KE; Tay S; Wen LS
J Adolesc Health; 2017 May; 60(5):483-486. PubMed ID: 28433118
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation.
Young AC; Schwarz E; Medina G; Obafemi A; Feng SY; Kane C; Kleinschmidt K
Am J Emerg Med; 2012 Sep; 30(7):1320.e5-7. PubMed ID: 21802885
[TBL] [Abstract][Full Text] [Related]
16. A review on the abuse of three NPS (synthetic cannabinoids, kratom, poppers) among youths in Asia.
Bae K; Kwon NJ; Han E
Forensic Sci Int; 2018 Nov; 292():45-49. PubMed ID: 30273913
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Predictors of Synthetic Cannabinoid Use in Adolescents.
Ninnemann AL; Jeong Choi H; Stuart GL; Temple JR
Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289139
[TBL] [Abstract][Full Text] [Related]
18. Myocardial infarction associated with use of the synthetic cannabinoid K2.
Mir A; Obafemi A; Young A; Kane C
Pediatrics; 2011 Dec; 128(6):e1622-7. PubMed ID: 22065271
[TBL] [Abstract][Full Text] [Related]
19. Geographic distribution of synthetic cannabinoid exposures reported to Texas poison centers.
Forrester MB; Haywood T
Am J Drug Alcohol Abuse; 2012 Nov; 38(6):603-8. PubMed ID: 22571605
[TBL] [Abstract][Full Text] [Related]
20. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
Winstock A; Lynskey M; Borschmann R; Waldron J
J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
